Group 2C: Novel Targets, Treatment Resistance, Triple Negative Breast Cancer

Thursday, Sept 15
2:00 pm – 3:30 pm Eastern Time (US/New York)

Poster #1: 

Prognostic and Therapeutic Roles of Lig1 in Triple Negative Breast Cancer Progression

Poster author Anh M. Tran-Huynh, Ph.D. Candidate will attend this session

Poster #2:

Non-Apoptotic, CSC-Directed Cell Death in Triple Negative Breast Cancer Induced by Ophiobolin A

Mentor: Lynda Weatherby

Lynda Weatherby has been living with Metastatic Breast Cancer since May 2013, and probably for years before that. Her diagnosis of MBC came 12 years after her early-stage diagnosis of “Stage 0 DCIS” and bilateral mastectomy 2001. She was told that “one rogue cell” must have been the cause of the metastatic spread throughout her bones, to her brain, and a very painful facial nerve over a decade after her first diagnosis. Her treatment has included radiation to the spine, two rounds of Gamma Knife radiation to the brain and facial nerve, and continual systemic hormonal treatment since 2013. After progression in 2018-2021, Lynda is on her first chemotherapy now and doing well with a “new normal”.

Lynda is passionate about MBC research and advocacy to make things better for all MBC patients. She is currently serving on the Executive Committee of the MBC Alliance, and on the production team of the Our MBC Life Podcast. She also co-founded and co-chairs the Northwest MBC Conference in Seattle, which will resume as an in-person event September 2022.

Twitter: @lyndaweatherby

Scientist: Traci Bethea, Ph.D.

Dr. Traci N. Bethea is an Assistant Professor in the Office of Minority Health and Health Disparities Research and the Cancer Prevention and Control Program at Georgetown Lombardi Comprehensive Cancer Center. Her research focuses on chemical and non-chemical stressors underlying cancer health disparities affecting Black women with a particular focus on estrogen receptor negative breast cancer and ovarian cancer. Her current work continues research on breast cancer subtypes in African American women and also examines risk factors for ovarian cancer and for sleep disturbances. Her research on modifiable factors and breast cancer survivorship is supported by a career development award from the National Cancer Institute. New research directions involve the study of environmental and social factors as predictors of health disparities in cancer incidence and survivorship and aims to “bridge the gap” between the biologic, individual, and macroenvironmental levels. Dr. Bethea received a PhD in Environmental Health from Boston University School of Public Health and completed postdoctoral training in cancer epidemiology with the Black Women’s Health Study at the Slone Epidemiology Center at Boston University.

Twitter: @shelovesepi